New drug cocktail targets Hard-to-Treat cancers
NCT ID NCT07650825
First seen Jun 19, 2026 · Last updated Jun 19, 2026
Summary
This early-stage trial is testing two experimental drugs, OVV-01 and AK112, in 30 people with advanced solid tumors that have not responded to standard treatments. OVV-01 is given both into a vein and directly into the tumor, while AK112 is given into a vein. The main goals are to check safety and find the right dose, not yet to prove the treatment works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
Hebei, Langfang, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
OVV-01 (a drug given into a vein and directly into tumors) and AK112 (another drug given into a vein)
What this could lead to
If it works, this could point toward a new combination treatment for advanced solid tumors that have not responded to other therapies.
What could go wrong
This is a very early (Phase 1) and small (30 people) trial focused on safety and dosing, not on proving the treatment works. The drugs may cause side effects or fail to shrink tumors.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.